Novo Nordisk Offers Wegovy Through Telehealth Providers, Including Hims & Hers

Novo Nordisk is expanding patient access to Wegovy (semaglutide) by enabling select telehealth providers to work directly through NovoCare Pharmacy. Patients working with Hims & Hers Health, LifeMD and Ro can now access Wegovy injection 2.4 mg through CenterWell Pharmacy, which is the dispensing pharmacy managing prescription fulfillment and delivery for NovoCare Pharmacy.

Dave Moore

“Wegovy continues to be in high demand as there are 100 million Americans living with obesity,” Dave Moore, executive vice president, U.S. Operations and President, of Novo Nordisk, said in a news release.

The demand for GLP-1 drugs such as Wegovy and Lilly’s Zepbound (tirzepatide) for weight loss is increasing. A PwC survey in October 2024 found that 8% to 10% of Americans are currently taking GLP-1 drugs, and 30% to 35% of Americans are interested in using them.

In the news release, Moore said offering Wegovy through telehealth providers helps patients, “including those embracing the growing telehealth community, [who] deserve to get the real thing” instead of relying on compounded products.

FDA officials have expressed concern about the safety of compounded GLP-1 products, issuing an update in March 2025 about multiple reports of adverse events and dosing errors from compounded obesity drugs. As of Feb. 28, 2025, the FDA has received more than 455 reports of adverse events with compounded semaglutide and more than 320 reports of adverse events with compounded tirzepatide.

Agency officials said some of the compounded GLP-1 therapies are using the salt forms, including semaglutide sodium and semaglutide acetate, which are different active ingredients than are used in the approved drugs. Regulators said they do not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug.

In a separate news release, Hims & Hers Health officials said it is offering Wegovy along with membership and its clinical support and nutrition guidance program for a price starting at $599 a month.

The two companies are also developing a roadmap that combines Novo Nordisk’s treatments with Hims & Hers’ ability to scale access to care for other therapies.

Related: Novo Nordisk Lowers Wegovy Price for Cash-Paying Patients

In March 2025, Novo Nordisk launched NovoCarePharmacy to provide direct-to-patient shipments of all dose strengths of Wegovy at a price of $499 per month. Additionally, Novo Nordisk updated the Wegovy savings program to allow patients to access the lowered cost of Wegovy at retail pharmacies.

Previously, Novo Nordisk offered a $650 per month direct-ship option for cash-paying patients.

Wegovy was approved to treat obesity in June 2021, and it is available as an injection in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg of the once-weekly, single-dose pen. Its list price is $1,349, and the company said that 90% of patients have a co-pay of $0 to $25 per month.

In 2024, sales of Wegovy and Novo Nordisk’s other semaglutide products (Ozempic and Rybelsus, which both treat type 2 diabetes) increased 27% to $39.4 billion.  Sales of Wegovy alone grew 57% to $9.4 billion.

The three semaglutide drugs are at the top of CMS's next 15 Medicare Part D drugs to be subject to price negotiations as part of the Inflation Reduction Act. Negotiations with participating drug companies begin this year, and the new prices will become effective in 2027. The three semaglutide products had total Part D gross costs of $14.4 billion from November 2023 to October 2024, according to CMS.